Clinical trial Recruiting at 2 sites Interventional Ages 18 to 65

Home-based cognitive-motor training for multiple sclerosis

Official title: Cognitive-motor Telerehabilitation in Multiple Sclerosis

Run by Universitair Ziekenhuis Brussel · NCT05355389 · Data updated 2026-11-12

This study is testing whether a home-based program that combines thinking and movement exercises can help people with multiple sclerosis more than traditional separate treatments.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment90 (estimated)
SponsorUniversitair Ziekenhuis Brussel
Academic / other
Locations2 sites (Brussels and 1 other locations)
StatusRecruiting
StartedSeptember 1, 2022
Main results expectedAugust 31, 2027
Study endsAugust 31, 2027
Registry record updatedMay 8, 2026
Trial IDNCT05355389 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 65 with clinically definite multiple sclerosis and specific cognitive impairments.

Probably not a fit

Patients with recent cognitive rehabilitation or significant psychiatric disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to evaluate the effectiveness of a home-based cognitive-motor training program for individuals with multiple sclerosis (MS). It will compare the combined cognitive-motor rehabilitation approach to traditional single cognitive and motor rehabilitation methods. The study will utilize a randomized controlled design across two centers, incorporating telemedicine to enhance accessibility. Participants will undergo assessments using MRI and EEG to identify changes in brain function and structure, as well as predictors of treatment response.

Why it matters

Potential benefit: If successful, this program could significantly enhance cognitive function and walking performance in patients with multiple sclerosis.

How similar studies have gone: Previous studies have shown promise in cognitive-motor rehabilitation for MS, but this specific approach using telerehabilitation is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinically definite multiple sclerosis (revised McDonald criteria 2017)
* Expanded Disability Status Scale (EDSS) below 6.0
* Digit span backwards z-score between \[-3 and -0.5\] standard deviations below the median of the normative values
* Age between 18 and 65
* Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)

Exclusion Criteria:

* Cognitive rehabilitation within six months before inclusion
* Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
* Start of or switch in immunomodulator treatment within three months before inclusion
* Less than one month post-exacerbation
* Major psychiatric or medical disorder that could influence cognitive functions
* Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
* Unable or unwilling to undergo EEG or MRI
* Refusing informed consent

Where it's running

  • Universitair Ziekenhuis Brussel
    Brussels, Belgium
    Recruiting
  • National MS Center Melsbroek
    Melsbroek, Belgium
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.